EW RSI Chart
Last 7 days
1.6%
Last 30 days
8.9%
Last 90 days
23.7%
Trailing 12 Months
24.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 5.5B | 5.7B | 5.8B | 6.0B |
2022 | 5.4B | 5.4B | 5.4B | 5.4B |
2021 | 4.5B | 4.9B | 5.1B | 5.2B |
2020 | 4.5B | 4.3B | 4.4B | 4.4B |
2019 | 3.8B | 4.0B | 4.2B | 4.3B |
2018 | 3.4B | 3.5B | 3.6B | 3.7B |
2017 | 3.1B | 3.2B | 3.3B | 3.4B |
2016 | 2.6B | 2.7B | 2.9B | 3.0B |
2015 | 2.4B | 2.4B | 2.4B | 2.5B |
2014 | 2.1B | 2.1B | 2.2B | 2.3B |
2013 | 1.9B | 2.0B | 2.0B | 2.0B |
2012 | 1.7B | 1.8B | 1.8B | 1.9B |
2011 | 1.5B | 1.6B | 1.6B | 1.7B |
2010 | 1.3B | 1.4B | 1.4B | 1.4B |
2009 | 1.3B | 1.3B | 1.3B | 1.3B |
2008 | 0 | 0 | 0 | 1.2B |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 13, 2024 | bobo donald e jr | acquired | 532,875 | 36.75 | 14,500 | cvp,strategy/corp development |
Mar 13, 2024 | bobo donald e jr | sold | -1,319,700 | 91.0135 | -14,500 | cvp,strategy/corp development |
Mar 11, 2024 | lemercier jean-luc m | sold | -1,320,150 | 91.677 | -14,400 | cvp, emeacla and japac |
Mar 11, 2024 | lemercier jean-luc m | acquired | 529,200 | 36.75 | 14,400 | cvp, emeacla and japac |
Mar 07, 2024 | lippis daniel j. | sold | -156,031 | 90.98 | -1,715 | cvp, japac |
Mar 07, 2024 | lippis daniel j. | acquired | 63,026 | 36.75 | 1,715 | cvp, japac |
Mar 04, 2024 | mussallem michael a | acquired | 1,078,610 | 36.75 | 29,350 | - |
Mar 04, 2024 | mussallem michael a | sold | -2,543,740 | 86.6691 | -29,350 | - |
Feb 29, 2024 | ullem scott b. | acquired | 266,621 | 36.75 | 7,255 | cvp, chief financial officer |
Feb 29, 2024 | ullem scott b. | sold | -620,923 | 85.5855 | -7,255 | cvp, chief financial officer |
Which funds bought or sold EW recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 26, 2024 | Fairman Group, LLC | new | - | 2,745 | 2,745 | -% |
Mar 26, 2024 | HighPoint Advisor Group LLC | new | - | 1,167,000 | 1,167,000 | 0.08% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | reduced | -6.2 | 1,620,990 | 51,640,400 | 0.04% |
Mar 21, 2024 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | added | 4,550 | 6,952 | 7,091 | -% |
Mar 19, 2024 | Accent Capital Management, LLC | new | - | 308,050 | 308,050 | 0.24% |
Mar 18, 2024 | CoreFirst Bank & Trust | unchanged | - | 16,728 | 183,000 | 0.12% |
Mar 15, 2024 | B. Riley Wealth Advisors, Inc. | reduced | -44.58 | -569,164 | 890,219 | 0.02% |
Mar 14, 2024 | ABLES, IANNONE, MOORE & ASSOCIATES, INC. | new | - | 305 | 305 | -% |
Mar 12, 2024 | Spartan Planning & Wealth Management | new | - | 20,435 | 20,435 | 0.02% |
Mar 12, 2024 | Cove Private Wealth, LLC | new | - | 973,636 | 973,636 | 0.92% |
Unveiling Edwards Lifesciences Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index
Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.
Returns of $10,000 invested in:
Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022
Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.
Peers (Alternatives to Edwards Lifesciences Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 196.9B | 40.1B | 34.4 | 4.91 | ||||
BDX | 71.2B | 19.5B | 56.69 | 3.65 | ||||
ALGN | 24.6B | 3.9B | 55.33 | 6.38 | ||||
BAX | 21.7B | 14.8B | 8.16 | 1.46 | ||||
MID-CAP | ||||||||
BIO | 10.2B | 2.7B | -16.04 | 3.83 | ||||
HSIC | 9.7B | 12.3B | 23.21 | 0.78 | ||||
ATR | 9.5B | 3.5B | 33.57 | 2.74 | ||||
XRAY | 6.9B | 4.0B | -51.36 | 1.74 | ||||
AXNX | 3.5B | 366.4M | -577.22 | 9.59 | ||||
PDCO | 2.5B | 6.6B | 12.86 | 0.38 | ||||
SMALL-CAP | ||||||||
AHCO | 1.5B | 3.2B | -2.23 | 0.47 | ||||
ANIK | 379.3M | 166.7M | -4.59 | 2.28 | ||||
ANGO | 227.2M | 329.5M | -16.09 | 0.69 | ||||
APYX | 43.3M | 52.3M | -2.31 | 0.83 | ||||
AEMD | 4.5M | 3.7M | -0.37 | 1.19 |
Edwards Lifesciences Corp News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 3.6% | 1,534 | 1,481 | 1,530 | 1,460 | 1,348 | 1,319 | 1,374 | 1,341 | 1,330 | 1,310 | 1,376 | 1,217 | 1,192 | 1,141 | 925 | 1,129 | 1,174 | 1,094 | 1,087 | 993 | 978 |
Gross Profit | 4.1% | 1,177 | 1,131 | 1,187 | 1,130 | 1,090 | 1,065 | 1,105 | 1,042 | 1,020 | 999 | 1,042 | 923 | 895 | 860 | 687 | 864 | 888 | 802 | 783 | 761 | 743 |
S&GA Expenses | 9.2% | 480 | 440 | 469 | 436 | 411 | 377 | 409 | 370 | 424 | 364 | 375 | 331 | 339 | 307 | 275 | 308 | 347 | 306 | 309 | 280 | 288 |
R&D Expenses | -0.1% | 270 | 270 | 270 | 261 | 232 | 234 | 251 | 229 | 233 | 238 | 225 | 207 | 196 | 196 | 182 | 187 | 194 | 196 | 192 | 171 | 163 |
EBITDA Margin | -6.4% | 0.29* | 0.31* | 0.31* | 0.34* | 0.36* | 0.34* | 0.34* | 0.36* | 0.35* | 0.36* | 0.36* | 0.24* | - | - | - | - | - | - | - | - | - |
Interest Expenses | -200.7% | -15.20 | 15.00 | 9.00 | 9.00 | 11.00 | 7.00 | 1.00 | 1.00 | 20.00 | -0.80 | -1.00 | 0.00 | 9.00 | 1.00 | 2.00 | 5.00 | 14.00 | 3.00 | 2.00 | 2.00 | 30.00 |
Income Taxes | -6.5% | 52.00 | 56.00 | 33.00 | 58.00 | 61.00 | 64.00 | 58.00 | 63.00 | 41.00 | 51.00 | 56.00 | 51.00 | 47.00 | 39.00 | -46.30 | 54.00 | 35.00 | 27.00 | 29.00 | 28.00 | -77.90 |
Earnings Before Taxes | -4.0% | 422 | 439 | 339 | 399 | 459 | 407 | 465 | 436 | 376 | 391 | 546 | 389 | 356 | 364 | -168 | 365 | 316 | 302 | 271 | 278 | -1.80 |
EBT Margin | -5.3% | 0.27* | 0.28* | 0.28* | 0.31* | 0.33* | 0.31* | 0.31* | 0.33* | 0.33* | 0.33* | 0.34* | 0.21* | - | - | - | - | - | - | - | - | - |
Net Income | -3.7% | 371 | 385 | 306 | 341 | 398 | 344 | 406 | 374 | 335 | 340 | 490 | 338 | 310 | 325 | -121 | 311 | 280 | 275 | 242 | 250 | 7.00 |
Net Income Margin | -5.0% | 0.23* | 0.25* | 0.25* | 0.27* | 0.28* | 0.27* | 0.27* | 0.29* | 0.29* | 0.29* | 0.30* | 0.19* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -86.4% | 48.00 | 356 | -14.30 | 253 | 214 | 250 | 289 | 221 | 284 | 471 | 457 | 195 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -0.1% | 9,363 | 9,371 | 9,004 | 8,651 | 8,293 | 8,638 | 8,425 | 8,420 | 8,503 | 8,160 | 7,662 | 7,214 | 7,237 | 6,801 | 6,424 | 6,076 | 6,488 | 5,966 | 5,574 | 5,469 | 5,324 |
Current Assets | -0.8% | 4,036 | 4,068 | 3,647 | 3,257 | 3,096 | 3,514 | 3,263 | 3,241 | 3,181 | 3,516 | 3,323 | 3,069 | 3,091 | 2,980 | 2,690 | 2,508 | 2,984 | 2,740 | 2,355 | 2,369 | 2,287 |
Cash Equivalents | -18.9% | 1,144 | 1,410 | 1,043 | 873 | 769 | 1,252 | 1,203 | 1,035 | 863 | 1,520 | 1,326 | 1,191 | 1,200 | 1,030 | 909 | 668 | 1,184 | 1,187 | 727 | 709 | 716 |
Inventory | 13.2% | 1,168 | 1,032 | 980 | 914 | 876 | 758 | 740 | 731 | 727 | 738 | 760 | 768 | 802 | 773 | 735 | 662 | 641 | 611 | 625 | 631 | 607 |
Net PPE | 4.1% | 1,749 | 1,681 | 1,662 | 1,646 | 1,633 | 1,566 | 1,560 | 1,552 | 1,547 | 1,465 | 1,446 | 1,418 | 1,395 | 1,276 | 1,196 | 1,101 | 1,060 | 974 | 931 | 892 | 868 |
Goodwill | -3.4% | 1,254 | 1,297 | 1,300 | 1,308 | 1,164 | 1,159 | 1,164 | 1,166 | 1,168 | 1,170 | 1,172 | 1,171 | 1,173 | 1,170 | 1,168 | 1,166 | 1,168 | 1,157 | 1,174 | 1,103 | 1,112 |
Liabilities | 0.0% | 2,644 | 2,644 | 2,558 | 2,589 | 2,486 | 2,420 | 2,482 | 2,575 | 2,667 | 2,619 | - | - | 2,663 | - | - | - | - | - | - | - | - |
Current Liabilities | -3.5% | 1,195 | 1,239 | 1,157 | 1,082 | 1,022 | 918 | 969 | 950 | 1,032 | 967 | 886 | 799 | 894 | 846 | 873 | 747 | 902 | 776 | 697 | 647 | 877 |
Long Term Debt | 0.0% | 597 | 597 | 597 | 597 | 596 | 596 | 596 | 596 | 596 | 596 | 595 | 595 | 595 | 595 | 595 | 595 | 594 | 594 | 594 | 594 | 594 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | 0.0% | 597 | 597 | 597 | 597 | 596 | 596 | 596 | 596 | 596 | 596 | 595 | 595 | 595 | 595 | 595 | 595 | 594 | 594 | 594 | 594 | 594 |
Shareholder's Equity | -0.1% | 6,650 | 6,658 | 6,447 | 6,062 | 5,807 | 6,218 | 5,944 | 5,845 | 5,836 | 5,541 | 5,133 | 4,658 | 4,574 | 4,210 | 3,839 | 3,901 | 4,148 | 3,815 | 3,500 | 3,448 | 3,140 |
Retained Earnings | 4.3% | 8,992 | 8,623 | 8,238 | 7,931 | 7,590 | 7,192 | 6,848 | 6,442 | 6,068 | 5,733 | 5,393 | 4,903 | 4,565 | 4,256 | 3,930 | 4,052 | 3,742 | 3,461 | 3,187 | 2,944 | 2,695 |
Additional Paid-In Capital | 2.9% | 2,274 | 2,211 | 2,146 | 2,049 | 1,969 | 1,915 | 1,853 | 1,769 | 1,700 | 1,643 | 1,579 | 1,497 | 1,438 | 1,382 | 1,324 | 1,676 | 1,623 | 1,570 | 1,512 | 1,449 | 1,384 |
Accumulated Depreciation | - | 857 | - | - | - | 750 | - | - | - | 655 | - | - | - | 599 | - | - | - | 512 | - | - | - | 455 |
Shares Outstanding | -0.9% | 601 | 607 | 608 | 606 | 608 | 620 | 622 | 622 | 623 | 623 | 622 | 623 | - | - | - | - | - | - | - | - | - |
Minority Interest | -0.3% | 69.00 | 70.00 | 71.00 | 84.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 56,850 | - | - | - | 58,454 | - | - | - | 64,028 | - | - | - | 42,641 | - | - | - | 34,109 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -66.8% | 137 | 412 | 34.00 | 314 | 283 | 310 | 332 | 293 | 374 | 532 | 526 | 301 | 400 | 216 | 231 | 207 | 403 | 437 | 341 | 2.00 | 293 |
Share Based Compensation | -6.4% | 31.00 | 33.00 | 37.00 | 39.00 | 28.00 | 30.00 | 36.00 | 32.00 | 24.00 | 27.00 | 30.00 | 28.00 | 21.00 | 23.00 | 25.00 | 24.00 | 18.00 | 20.00 | 22.00 | 21.00 | 16.00 |
Cashflow From Investing | -84.2% | 14.00 | 89.00 | 70.00 | 1.00 | 95.00 | -201 | 130 | 230 | -965 | -377 | -329 | -49.70 | -259 | -126 | -10.20 | -134 | -445 | -12.70 | -88.30 | -49.50 | 6.00 |
Cashflow From Financing | -188.3% | -413 | -143 | 52.00 | -206 | -838 | -69.90 | -308 | -368 | -62.00 | 39.00 | -59.00 | -274 | 41.00 | 34.00 | 24.00 | -586 | 37.00 | 34.00 | -231 | 44.00 | -844 |
Buy Backs | 157.1% | 448 | 174 | 8.00 | 249 | 866 | 100 | 355 | 406 | 97.00 | 2.00 | 112 | 303 | 0.00 | 1.00 | 9.00 | 615 | - | 1.00 | 256 | 6.00 | 272 |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | |||
Net sales | $ 6,004.8 | $ 5,382.4 | $ 5,232.5 |
Cost of sales | 1,379.8 | 1,080.4 | 1,248.9 |
Gross profit | 4,625.0 | 4,302.0 | 3,983.6 |
Selling, general, and administrative expenses | 1,824.6 | 1,567.6 | 1,493.7 |
Research and development expenses | 1,071.8 | 945.2 | 903.1 |
Intellectual property agreement and litigation expense (Note 3) | 203.5 | 15.8 | 20.6 |
Change in fair value of contingent consideration liabilities (Note 12) | (26.2) | (35.8) | (124.1) |
Special charge and separation costs (Note 4) | 17.2 | 60.7 | 0.0 |
Operating income | 1,534.1 | 1,748.5 | 1,690.3 |
Interest expense | 17.6 | 19.2 | 18.4 |
Interest income | (67.2) | (35.5) | (17.4) |
Other income, net (Note 17) | (14.4) | (2.6) | (12.7) |
Income before provision for income taxes | 1,598.1 | 1,767.4 | 1,702.0 |
Provision for income taxes (Note 18) | 198.7 | 245.5 | 198.9 |
Net income | 1,399.4 | 1,521.9 | 1,503.1 |
Net loss attributable to noncontrolling interest | (3.0) | 0.0 | 0.0 |
Net income attributable to Edwards Lifesciences Corporation. | $ 1,402.4 | $ 1,521.9 | $ 1,503.1 |
Earnings per share attributable to Edwards Lifesciences Corporation: | |||
Basic (in dollars per share) | $ 2.31 | $ 2.46 | $ 2.41 |
Diluted (in dollars per share) | $ 2.30 | $ 2.44 | $ 2.38 |
Weighted-average number of common shares outstanding attributable to Edwards Lifesciences Corporation: | |||
Basic (in shares) | 606.7 | 619.0 | 623.3 |
Diluted (in shares) | 609.4 | 624.2 | 631.2 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 1,144.0 | $ 769.0 |
Short-term investments (Note 7) | 500.5 | 446.3 |
Accounts receivable, net of allowances of $8.3 and $7.9, respectively | 775.1 | 643.0 |
Other receivables | 61.8 | 56.1 |
Inventories (Note 5) | 1,168.2 | 875.5 |
Prepaid expenses | 146.8 | 110.0 |
Other current assets | 239.3 | 195.9 |
Total current assets | 4,035.7 | 3,095.8 |
Long-term investments (Note 7) | 583.9 | 1,239.0 |
Property, plant, and equipment, net (Note 5) | 1,749.4 | 1,632.8 |
Operating lease right-of-use assets (Note 6) | 94.0 | 92.3 |
Goodwill (Note 10) | 1,253.5 | 1,164.3 |
Other intangible assets, net (Note 10) | 428.4 | 285.2 |
Deferred income taxes | 754.6 | 484.0 |
Other assets | 463.7 | 299.1 |
Total assets | 9,363.2 | 8,292.5 |
Current liabilities | ||
Accounts payable | 201.4 | 201.9 |
Accrued and other liabilities (Note 5) | 969.1 | 795.0 |
Operating lease liabilities (Note 6) | 24.9 | 25.5 |
Total current liabilities | 1,195.4 | 1,022.4 |
Long-term debt (Note 11) | 597.0 | 596.3 |
Contingent consideration liabilities (Note 12) | 0.0 | 26.2 |
Taxes payable (Note 18) | 80.6 | 143.4 |
Operating lease liabilities (Note 6) | 73.0 | 69.5 |
Uncertain tax positions (Note 18) | 339.3 | 267.5 |
Litigation settlement accrual (Note 3) | 94.2 | 143.0 |
Other liabilities | 264.3 | 217.5 |
Total liabilities | 2,643.8 | 2,485.8 |
Commitments and contingencies (Notes 6, 11, and 19) | ||
Stockholders' equity (Note 15) | ||
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding | 0.0 | 0.0 |
Common stock, $1.00 par value, 1,050.0 shares authorized, 650.5 and 646.3 shares issued, and 601.1 and 608.3 shares outstanding, respectively | 650.5 | 646.3 |
Additional paid-in capital | 2,274.4 | 1,969.3 |
Retained earnings | 8,992.4 | 7,590.0 |
Accumulated other comprehensive loss (Note 16) | (242.8) | (254.9) |
Treasury stock, at cost, 49.4 and 38.0 shares, respectively | (5,024.5) | (4,144.0) |
Total Edwards Lifesciences Corporation stockholders' equity | 6,650.0 | 5,806.7 |
Noncontrolling interest (Note 9) | 69.4 | 0.0 |
Total stockholders' equity | 6,719.4 | 5,806.7 |
Total liabilities and stockholders' equity | $ 9,363.2 | $ 8,292.5 |